Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Cumberland to sell drug portfolio to Apotex for $100m

 April 24, 2026

Pharmaceutical Technology

Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canada-based Apotex for $100m in cash.

M&A / DealsRead full story

Post navigation

FDA approves Regeneron’s hearing loss gene therapy →
← FDA clears first genetic hearing loss gene therapy

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com